세계의 근위축성 측색 경화증 치료 시장 : 성장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 713.3 million in 2023 and is expected to grow at a CAGR of 5.5% from 2024 to 2032. This growth is driven by the increasing prevalence of ALS, growing awareness about the condition, advancements in therapeutic technologies, and the continuous development of innovative treatment methods. Significant advancements in diagnostic technologies have enhanced the early detection and management of ALS. Improved neuroimaging techniques, genetic testing, and biomarker research allows healthcare providers to diagnose the disease at earlier stages, facilitating personalized treatment plans that contribute to market expansion. In terms of treatment types, the market is divided into medication, stem cell therapy, and other approaches.

In 2023, the medication segment led the market with a value of USD 479.7 million. This segment focuses on pharmaceutical treatments aimed at managing ALS symptoms and slowing disease progression. Medications like riluzole and edaravone are commonly used to prolong survival and reduce neuron damage, thereby addressing a key area of demand in ALS treatment. When segmented by disease type, sporadic ALS dominated the market with 87.3% share in 2023. Sporadic ALS is the most common form of the disease, accounting for 90-95% of cases.

It lacks a clear genetic link, which poses additional challenges in treatment compared to familial ALS. However, the widespread prevalence of this form continues to drive demand for innovative therapeutic solutions. North America plays a crucial role in the ALS treatment market, with the region expected to grow at a CAGR of 5.2% and reach USD 515.6 million by 2032. The U.S. is a key contributor due to the high prevalence of ALS, supported by a strong healthcare infrastructure and significant research and development efforts. Numerous clinical trials are underway in the U.S. to explore more effective treatments, reflecting the country's commitment to expanding therapeutic options for ALS patients

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of amyotrophic lateral sclerosis (ALS) globally
    • 3.2.1.2 Growing awareness and early diagnosis of ALS
    • 3.2.1.3 Development of novel drug therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with treatment
    • 3.2.2.2 Side effects associated with treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Riluzole
  • 5.2.2 Edaravone
  • 5.2.3 Nuedexta
  • 5.2.4 Other medication types
• 5.3 Stem cell therapy
• 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Sporadic ALS
• 6.3 Familial ALS

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Rehabilitation centers
• 8.4 Specialty clinics
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia-Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia-Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AB Science
• 10.2 Biogen Inc.
• 10.3 Biohaven Pharmaceutical (Pfizer, Inc.)
• 10.4 BrainStorm Therapeutics, Inc.
• 10.5 Corestemchemon Inc.
• 10.6 Eledon Pharmaceuticals, Inc.
• 10.7 F. Hoffmann-La Roche Ltd
• 10.8 Ionis Pharmaceuticals, Inc.
• 10.9 ITF Pharma GmbH
• 10.10 Mitsubishi Tanabe Pharma Corporation
• 10.11 Otsuka America Pharmaceutical, Inc.
• 10.12 Sun Pharmaceutical Industries, Ltd.